Lilly’s Glyxambi Is First SGLT2/DPP-4 Combo Product For Diabetes
This article was originally published in The Pink Sheet Daily
Executive Summary
Glyxambi is the latest in a series of new diabetes drugs for Eli Lilly, following on the heels of Jardiance and Trulicity. The company highlighted new drugs and its pipeline during its year-end financial call.